|
1
|
Uchida D, Begum NM, Almofti A, Nakashiro
K, Kawamata H, Tateishi Y, Hamakawa H, Yoshida H and Sato M:
Possible role of stromal-cell-derived factor-1/CXCR4 signaling on
lymph node metastasis of oral squamous cell carcinoma. Exp Cell
Res. 290:289–302. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Uchida D, Begum NM, Tomizuka Y, Bando T,
Almofti A, Yoshida H and Sato M: Acquisition of lymph node, but not
distant metastatic potentials, by the overexpression of CXCR4 in
human oral squamous cell carcinoma. Lab Invest. 84:1538–1546. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Almofti A, Uchida D, Begum NM, Tomizuka Y,
Iga H, Yoshida H and Sato M: The clinicopathological significance
of the expression of CXCR4 protein in oral squamous cell carcinoma.
Int J Oncol. 25:65–71. 2004.PubMed/NCBI
|
|
4
|
Onoue T, Uchida D, Begum NM, Tomizuka Y,
Yoshida H and Sato M: Epithelial-mesenchymal transition induced by
the stromal cell-derived factor-1/CXCR4 system in oral squamous
cell carcinoma cells. Int J Oncol. 29:1133–1138. 2006.PubMed/NCBI
|
|
5
|
Uchida D, Onoue T, Tomizuka Y, Begum NM,
Miwa Y, Yoshida H and Sato M: Involvement of an autocrine stromal
cell derived factor-1/CXCR4 system on the distant metastasis of
human oral squamous cell carcinoma. Mol Cancer Res. 5:685–694.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Uchida D, Kuribayashi N, Kinouchi M, Ohe
G, Tamatani T, Nagai H and Miyamoto Y: Expression and function of
CXCR4 in human salivary gland cancers. Clin Exp Metastasis.
30:133–142. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Uchida D, Onoue T, Kuribayashi N, Tomizuka
Y, Tamatani T, Nagai H and Miyamoto Y: Blockade of CXCR4 in oral
squamous cell carcinoma inhibits lymph node metastases. Eur J
Cancer. 47:452–459. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
De Clercq E: The bicyclam AMD3100 story.
Nat Rev Drug Discov. 2:581–587. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Genzyme: Investigator's Brochure for
Plerixafor Injection (AMD3100, Mozobil). 1–142. 2012.
|
|
10
|
Müller A, Homey B, Soto H, Ge N, Catron D,
Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al:
Involvement of chemokine receptors in breast cancer metastasis.
Nature. 410:50–56. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Scotton CJ, Wilson JL, Milliken D, Stamp G
and Balkwill FR: Epithelial cancer cell migration: A role for
chemokine receptors? Cancer Res. 61:4961–4965. 2001.PubMed/NCBI
|
|
12
|
Taichman RS, Cooper C, Keller ET, Pienta
KJ, Taichman NS and McCauley LK: Use of the stromal cell-derived
factor-1/CXCR4 pathway in prostate cancer metastasis to bone.
Cancer Res. 62:1832–1837. 2002.PubMed/NCBI
|
|
13
|
Schrader AJ, Lechner O, Templin M, Dittmar
KE, Machtens S, Mengel M, Probst-Kepper M, Franzke A, Wollensak T,
Gatzlaff P, et al: CXCR4/CXCL12 expression and signalling in kidney
cancer. Br J Cancer. 86:1250–1256. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou Y, Larsen PH, Hao C and Yong VW:
CXCR4 is a major chemokine receptor on glioma cells and mediates
their survival. J Biol Chem. 277:49481–49487. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kijima T, Maulik G, Ma PC, Tibaldi EV,
Turner RE, Rollins B, Sattler M, Johnson BE and Salgia R:
Regulation of cellular proliferation, cytoskeletal function, and
signal transduction through CXCR4 and c-Kit in small cell lung
cancer cells. Cancer Res. 62:6304–6311. 2002.PubMed/NCBI
|
|
16
|
Cabioglu N, Summy J, Miller C, Parikh NU,
Sahin AA, Tuzlali S, Pumiglia K, Gallick GE and Price JE:
CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu
in breast cancer cells by a novel pathway involving Src kinase
activation. Cancer Res. 65:6493–6497. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hartmann TN, Burger JA, Glodek A, Fujii N
and Burger M: CXCR4 chemokine receptor and integrin signaling
co-operate in mediating adhesion and chemoresistance in small cell
lung cancer (SCLC) cells. Oncogene. 24:4462–4471. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yasumoto K, Koizumi K, Kawashima A, Saitoh
Y, Arita Y, Shinohara K, Minami T, Nakayama T, Sakurai H, Takahashi
Y, et al: Role of the CXCL12/CXCR4 axis in peritoneal
carcinomatosis of gastric cancer. Cancer Res. 66:2181–2187. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Marchesi F, Monti P, Leone BE, Zerbi A,
Vecchi A, Piemonti L, Mantovani A and Allavena P: Increased
survival, proliferation, and migration in metastatic human
pancreatic tumor cells expressing functional CXCR4. Cancer Res.
64:8420–8427. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Stone ND, Dunaway SB, Flexner C, Tierney
C, Calandra GB, Becker S, Cao YJ, Wiggins IP, Conley J, MacFarland
RT, et al: Multiple-dose escalation study of the safety,
pharmacokinetics, and biologic activity of oral AMD070, a selective
CXCR4 receptor inhibitor, in human subjects. Antimicrob Agents
Chemother. 51:2351–2358. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mosi RM, Anastassova V, Cox J, Darkes MC,
Idzan SR, Labrecque J, Lau G, Nelson KL, Patel K, Santucci Z, et
al: The molecular pharmacology of AMD11070: An orally bioavailable
CXCR4 HIV entry inhibitor. Biochem Pharmacol. 83:472–479. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Parameswaran R, Yu M, Lim M, Groffen J and
Heisterkamp N: Combination of drug therapy in acute lymphoblastic
leukemia with a CXCR4 antagonist. Leukemia. 25:1314–1323. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Morimoto M, Matsuo Y, Koide S, Tsuboi K,
Shamoto T, Sato T, Saito K, Takahashi H and Takeyama H: Enhancement
of the CXCL12/CXCR4 axis due to acquisition of gemcitabine
resistance in pancreatic cancer: Effect of CXCR4 antagonists. BMC
Cancer. 16:3052016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bleul CC, Farzan M, Choe H, Parolin C,
Clark-Lewis I, Sodroski J and Springer TA: The lymphocyte
chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1
entry. Nature. 382:829–833. 1996. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nagasawa T, Hirota S, Tachibana K,
Takakura N, Nishikawa S, Kitamura Y, Yoshida N, Kikutani H and
Kishimoto T: Defects of B-cell lymphopoiesis and bone-marrow
myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature.
382:635–638. 1996. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Oberlin E, Amara A, Bachelerie F, Bessia
C, Virelizier JL, Arenzana-Seisdedos F, Schwartz O, Heard JM,
Clark-Lewis I, Legler DF, et al: The CXC chemokine SDF-1 is the
ligand for LESTR/fusin and prevents infection by
T-cell-line-adapted HIV-1. Nature. 382:833–835. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Aiuti A, Webb IJ, Bleul C, Springer T and
Gutierrez-Ramos JC: The chemokine SDF-1 is a chemoattractant for
human CD34+ hematopoietic progenitor cells and provides
a new mechanism to explain the mobilization of CD34+
progenitors to peripheral blood. J Exp Med. 185:111–120. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hwang JH, Hwang JH, Chung HK, Kim DW,
Hwang ES, Suh JM, Kim H, You KH, Kwon OY, Ro HK, et al: CXC
chemokine receptor 4 expression and function in human anaplastic
thyroid cancer cells. J Clin Endocrinol Metab. 88:408–416. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang L, Yeger H, Das B, Irwin MS and
Baruchel S: Tissue microenvironment modulates CXCR4 expression and
tumor metastasis in neuroblastoma. Neoplasia. 9:36–46. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Scala S, Ottaiano A, Ascierto PA, Cavalli
M, Simeone E, Giuliano P, Napolitano M, Franco R, Botti G and
Castello G: Expression of CXCR4 predicts poor prognosis in patients
with malignant melanoma. Clin Cancer Res. 11:1835–1841. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Scala S: Molecular Pathways: Targeting the
CXCR4-CXCL12 axis - untapped potential in the tumor
microenvironment. Clin Cancer Res. 21:4278–4285. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Debnath B, Xu S, Grande F, Garofalo A and
Neamati N: Small molecule inhibitors of CXCR4. Theranostics.
3:47–75. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Skerlj RT, Bridger GJ, Kaller A, McEachern
EJ, Crawford JB, Zhou Y, Atsma B, Langille J, Nan S, Veale D, et
al: Discovery of novel small molecule orally bioavailable C-X-C
chemokine receptor 4 antagonists that are potent inhibitors of
T-tropic (X4) HIV-1 replication. J Med Chem. 53:3376–3388. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
O'Boyle G, Swidenbank I, Marshall H,
Barker CE, Armstrong J, White SA, Fricker SP, Plummer R, Wright M
and Lovat PE: Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by
AMD11070. Br J Cancer. 108:1634–1640. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tisdale MJ: Biology of cachexia. J Natl
Cancer Inst. 89:1763–1773. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Van Hout A, D'huys T, Oeyen M, Schols D
and Van Loy T: Comparison of cell-based assays for the
identification and evaluation of competitive CXCR4 inhibitors. PLoS
One. 12:e01760572017. View Article : Google Scholar : PubMed/NCBI
|
